Daily Ards Research Analysis

In patients with ARDS, serum POSTN was elevated and miR-19a-3p was reduced, with both markers associated with disease severity. In an LPS-induced mouse model and macrophage-based co-culture systems, honokiol attenuated lung injury and fibrotic responses, while reporter and loss-of-function experiments supported regulation through the miR-19a-3p/POSTN axis.

Impact: This study connects a clinically associated biomarker pattern with a mechanistically tested profibrotic pathway and identifies honokiol as a candidate intervention for a major unmet need: post-ARDS pulmonary fibrosis. Its translational value is strengthened by concordant patient, animal, and cell-based evidence, although efficacy in humans remains unestablished.

Clinical Implications: The miR-19a-3p/POSTN axis may support biomarker-guided risk stratification and therapeutic development for ARDS-associated fibrosis. Honokiol should be regarded as a preclinical candidate requiring pharmacokinetic, safety, dose-finding, and prospective clinical studies rather than as an established treatment.

Future Directions: Future work should validate POSTN and miR-19a-3p prospectively in well-characterized ARDS cohorts, define the cellular source and temporal behavior of the pathway, and conduct pharmacokinetic, toxicology, dose-finding, and randomized clinical studies of honokiol or more selective pathway modulators.

Among 274 medical ICU patients receiving volume-targeted ventilation, dual targeting was associated with a higher frequency of average delivered tidal volume above 8 mL/kg ideal body weight during the first 48 hours after intubation. This occurred despite similar set tidal volumes, and the association persisted after adjustment; adjusted clinical outcomes did not differ significantly.

Impact: The study identifies a practical, previously underappreciated pathway by which a comfort-oriented ventilator feature can undermine lung-protective ventilation. It directly informs bedside ventilator configuration and monitoring, even though causation and downstream harm were not demonstrated.

Clinical Implications: When dual targeting is enabled during volume control ventilation, clinicians should verify delivered rather than only set tidal volume, particularly during the first 48 hours of intubation and in patients at risk for ARDS. Institutions should evaluate ventilator defaults, alarms, and monitoring protocols before broad implementation.

Future Directions: Prospective multicenter studies should assess how patient effort, respiratory drive, ventilator algorithms, and clinical context influence excess delivered tidal volume, and should determine whether disabling or modifying dual targeting improves ventilator-free days, lung injury biomarkers, and mortality.

In this prospective cohort of 50 mechanically ventilated patients with ARDS, non-survivors had higher day-1 total, dynamic, and resistive mechanical power, as well as persistently adverse respiratory rate, plateau pressure, driving pressure, and total mechanical power during ICU care. Multivariate regression identified oxygenation, compliance, plateau pressure, and several mechanical power measures as independent mortality predictors, although the small sample makes the findings exploratory.

Impact: The study supports mechanical power as an integrated measure of potentially injurious ventilatory energy and emphasizes cumulative exposure rather than isolated ventilator variables. Its prospective serial measurements and quantitative CT assessment provide a useful foundation for larger studies of energy-based ventilator management.

Clinical Implications: Clinicians should consider respiratory rate, plateau pressure, driving pressure, compliance, and total mechanical power together when optimizing ventilation in ARDS. The findings support close monitoring and reduction of excessive cumulative mechanical energy, but they do not establish a mortality benefit from targeting a specific mechanical power threshold.

Future Directions: Larger multicenter cohorts should validate time-varying mechanical power thresholds, account for spontaneous breathing effort and mode of ventilation, and test whether protocolized reduction of cumulative mechanical power improves mortality and ventilator-free days in randomized trials.